BACKGROUND: Alcohol dependence (AD) is often accompanied by comorbid depression. Recent clinical evidence supports the benefit of subtype-specific pharmacotherapy in treating the population of alcohol-dependent subjects with comorbid major depressive disorder (MDD). However, in many alcohol-dependent subjects, depression is a reactive response to chronic alcohol use and withdrawal and abates with a period of abstinence. Genetic markers may distinguish alcohol-dependent subjects with MDD not tied chronologically and etiologically to their alcohol consumption. In this work, we investigated the association of adenylyl cyclase genes (ADCY1-9), which are implicated in both AD and mood disorders, with alcoholism and comorbid depression. METHODS: Subjects from Vienna, Austria (n = 323) were genotyped, and single nucleotide polymorphisms (1,152) encompassing the genetic locations of the 9 ADCY genes were examined. The Vienna cohort contained alcohol-dependent subjects differentiated using the Lesch Alcoholism Typology. In this typology, subjects are segregated into 4 types. Type III alcoholism is distinguished by co-occurrence of symptoms of depression and by affecting predominantly females. RESULTS: We identified 4 haplotypes associated with the phenotype of Type III alcoholism in females. One haplotype was in a genomic area in proximity to ADCY2, but actually within a lincRNA gene, 2 haplotypes were within ADCY5, and 1 haplotype was within the coding region of ADCY8. Three of the 4 haplotypes contributed independently to Type III alcoholism and together generated a positive predictive value of 72% and a negative predictive value of 78% for distinguishing women with a Lesch Type III diagnosis versus women designated as Type I or II alcoholics. CONCLUSIONS: Polymorphisms in ADCY8 and ADCY5 and within a lincRNA are associated with an alcohol-dependent phenotype in females, which is distinguished by comorbid signs of depression. Each of these genetic locations can rationally contribute to the polygenic etiology of the alcoholism/depression phenotype, and the use of these genetic markers may aid in choosing appropriate and beneficial treatment strategies.
BACKGROUND:Alcohol dependence (AD) is often accompanied by comorbid depression. Recent clinical evidence supports the benefit of subtype-specific pharmacotherapy in treating the population of alcohol-dependent subjects with comorbid major depressive disorder (MDD). However, in many alcohol-dependent subjects, depression is a reactive response to chronic alcohol use and withdrawal and abates with a period of abstinence. Genetic markers may distinguish alcohol-dependent subjects with MDD not tied chronologically and etiologically to their alcohol consumption. In this work, we investigated the association of adenylyl cyclase genes (ADCY1-9), which are implicated in both AD and mood disorders, with alcoholism and comorbid depression. METHODS: Subjects from Vienna, Austria (n = 323) were genotyped, and single nucleotide polymorphisms (1,152) encompassing the genetic locations of the 9 ADCY genes were examined. The Vienna cohort contained alcohol-dependent subjects differentiated using the Lesch Alcoholism Typology. In this typology, subjects are segregated into 4 types. Type III alcoholism is distinguished by co-occurrence of symptoms of depression and by affecting predominantly females. RESULTS: We identified 4 haplotypes associated with the phenotype of Type III alcoholism in females. One haplotype was in a genomic area in proximity to ADCY2, but actually within a lincRNA gene, 2 haplotypes were within ADCY5, and 1 haplotype was within the coding region of ADCY8. Three of the 4 haplotypes contributed independently to Type III alcoholism and together generated a positive predictive value of 72% and a negative predictive value of 78% for distinguishing women with a Lesch Type III diagnosis versus women designated as Type I or II alcoholics. CONCLUSIONS: Polymorphisms in ADCY8 and ADCY5 and within a lincRNA are associated with an alcohol-dependent phenotype in females, which is distinguished by comorbid signs of depression. Each of these genetic locations can rationally contribute to the polygenic etiology of the alcoholism/depression phenotype, and the use of these genetic markers may aid in choosing appropriate and beneficial treatment strategies.
Authors: Subhash C Pandey; Elena H Chartoff; William A Carlezon; Jian Zou; Huaibo Zhang; Arati S Kreibich; Julie A Blendy; Fulton T Crews Journal: Alcohol Clin Exp Res Date: 2005-02 Impact factor: 3.455
Authors: James W Maas; Sherri K Vogt; Guy C K Chan; Victor V Pineda; Daniel R Storm; Louis J Muglia Journal: J Neurosci Date: 2005-04-20 Impact factor: 6.167
Authors: Haley L Yarosh; Shashwath A Meda; Harriet de Wit; Amy B Hart; Godfrey D Pearlson Journal: Psychopharmacology (Berl) Date: 2015-04-07 Impact factor: 4.530
Authors: Sarah R Horn; Madison M Long; Benjamin W Nelson; Nicholas B Allen; Philip A Fisher; Michelle L Byrne Journal: Brain Behav Immun Date: 2018-06-19 Impact factor: 7.217
Authors: Erika J Wolf; Ann M Rasmusson; Karen S Mitchell; Mark W Logue; Clinton T Baldwin; Mark W Miller Journal: Depress Anxiety Date: 2014-03-27 Impact factor: 6.505
Authors: Carmen W Dessauer; Val J Watts; Rennolds S Ostrom; Marco Conti; Stefan Dove; Roland Seifert Journal: Pharmacol Rev Date: 2017-04 Impact factor: 25.468
Authors: Jeffrey M Witkin; Michael A Statnick; Linda M Rorick-Kehn; John E Pintar; Michael Ansonoff; Yanyun Chen; R Craig Tucker; Roberto Ciccocioppo Journal: Pharmacol Ther Date: 2013-11-01 Impact factor: 12.310
Authors: Katrina F Ostrom; Justin E LaVigne; Tarsis F Brust; Roland Seifert; Carmen W Dessauer; Val J Watts; Rennolds S Ostrom Journal: Physiol Rev Date: 2021-10-26 Impact factor: 37.312
Authors: Carmelo Ferrai; Elena Torlai Triglia; Jessica R Risner-Janiczek; Tiago Rito; Owen Jl Rackham; Inês de Santiago; Alexander Kukalev; Mario Nicodemi; Altuna Akalin; Meng Li; Mark A Ungless; Ana Pombo Journal: Mol Syst Biol Date: 2017-10-16 Impact factor: 11.429